J&J(JNJ) - 2026 Q3 - Quarterly Results

Supplementary Sales Data This section provides detailed sales performance data across various geographic regions and business segments for the third quarter and nine months ended 2025 Sales by Geographic Area Johnson & Johnson's worldwide sales demonstrated growth in both the third quarter and the nine months ended 2025, driven by strong performance in the U.S. and International markets, with operational growth being a key contributor Third Quarter Worldwide Sales by Geographic Area - Third Quarter | Metric | 2025 Sales ($M) | 2024 Sales ($M) | Total Change (%) | Operational Change (%) | | :-------------------------------- | :-------------- | :-------------- | :--------------- | :--------------------- | | Worldwide Sales | 23,993 | 22,471 | 6.8 | 5.4 | | U.S. Sales | 13,708 | 12,909 | 6.2 | 6.2 | | Europe Sales | 5,440 | 4,914 | 10.7 | 4.4 | | Western Hemisphere excl. U.S. Sales | 1,231 | 1,173 | 4.9 | 7.3 | | Asia-Pacific, Africa Sales | 3,614 | 3,475 | 4.0 | 3.4 | | International Sales | 10,285 | 9,562 | 7.6 | 4.4 | Nine Months Worldwide Sales by Geographic Area - Nine Months | Metric | 2025 Sales ($M) | 2024 Sales ($M) | Total Change (%) | Operational Change (%) | | :-------------------------------- | :-------------- | :-------------- | :--------------- | :--------------------- | | Worldwide Sales | 69,629 | 66,301 | 5.0 | 4.7 | | U.S. Sales | 39,557 | 37,098 | 6.6 | 6.6 | | Europe Sales | 15,937 | 15,291 | 4.2 | 1.5 | | Western Hemisphere excl. U.S. Sales | 3,604 | 3,579 | 0.7 | 7.6 | | Asia-Pacific, Africa Sales | 10,531 | 10,333 | 1.9 | 1.8 | | International Sales | 30,072 | 29,203 | 3.0 | 2.3 | Sales by Segment of Business Both the Innovative Medicine and MedTech segments contributed positively to overall sales growth in the third quarter and nine months ended 2025, with consistent operational growth across both segments Third Quarter Worldwide Sales by Segment of Business - Third Quarter | Segment | 2025 Sales ($M) | 2024 Sales ($M) | Total Change (%) | Operational Change (%) | | :---------------- | :-------------- | :-------------- | :--------------- | :--------------------- | | Innovative Medicine WW | 15,563 | 14,580 | 6.8 | 5.3 | | Innovative Medicine U.S. | 9,402 | 8,871 | 6.0 | 6.0 | | Innovative Medicine Intl | 6,161 | 5,709 | 7.9 | 4.3 | | MedTech WW | 8,430 | 7,891 | 6.8 | 5.6 | | MedTech U.S. | 4,306 | 4,038 | 6.6 | 6.6 | | MedTech Intl | 4,124 | 3,853 | 7.0 | 4.5 | Nine Months Worldwide Sales by Segment of Business - Nine Months | Segment | 2025 Sales ($M) | 2024 Sales ($M) | Total Change (%) | Operational Change (%) | | :---------------- | :-------------- | :-------------- | :--------------- | :--------------------- | | Innovative Medicine WW | 44,638 | 42,632 | 4.7 | 4.5 | | Innovative Medicine U.S. | 26,655 | 24,993 | 6.7 | 6.7 | | Innovative Medicine Intl | 17,983 | 17,639 | 1.9 | 1.3 | | MedTech WW | 24,991 | 23,669 | 5.6 | 5.3 | | MedTech U.S. | 12,902 | 12,105 | 6.6 | 6.6 | | MedTech Intl | 12,089 | 11,564 | 4.5 | 3.9 | Condensed Consolidated Statement of Earnings This section presents the condensed consolidated statement of earnings, highlighting key financial performance metrics for the third quarter and nine months ended 2025 Third Quarter In Q3 2025, Johnson & Johnson reported a significant increase in net earnings and diluted EPS, primarily driven by a substantial decrease in R&D expense and a positive swing in other (income) expense, net. Adjusted net earnings also showed healthy growth Condensed Consolidated Statement of Earnings - Third Quarter | Metric | 2025 ($M) | 2024 ($M) | % Increase (Decrease) | | :------------------------------------ | :-------- | :-------- | :-------------------- | | Sales to customers | 23,993 | 22,471 | 6.8 | | Cost of products sold | 7,303 | 6,963 | 4.9 | | Gross Profit | 16,690 | 15,508 | 7.6 | | Selling, marketing and administrative expenses | 5,922 | 5,478 | 8.1 | | Research and development expense | 3,672 | 4,952 | (25.8) | | Interest (income) expense, net | 18 | (99) | N/A | | Other (income) expense, net | (478) | 1,798 | N/A | | Restructuring | 63 | 41 | 53.7 | | Earnings before provision for taxes on income | 7,493 | 3,338 | 124.5 | | Provision for taxes on income | 2,341 | 644 | 263.5 | | Net earnings | 5,152 | 2,694 | 91.2 | | Net earnings per share (Diluted) | 2.12 | 1.11 | 91.0 | | Effective tax rate | 31.2% | 19.3% | N/A | | Adjusted net earnings | 6,801 | 5,876 | 15.7 | | Adjusted net earnings per share (Diluted) | 2.80 | 2.42 | 15.7 | | Adjusted effective tax rate | 19.4% | 19.3% | N/A | Nine Months For the nine months ended 2025, net earnings more than doubled, and diluted EPS saw a similar increase. This was largely influenced by a substantial positive shift in other (income) expense, net, and a reduction in R&D spending. Adjusted net earnings also grew, albeit at a more moderate pace Condensed Consolidated Statement of Earnings - Nine Months | Metric | 2025 ($M) | 2024 ($M) | % Increase (Decrease) | | :------------------------------------ | :-------- | :-------- | :-------------------- | | Sales to customers | 69,629 | 66,301 | 5.0 | | Cost of products sold | 22,288 | 20,343 | 9.6 | | Gross Profit | 47,341 | 45,958 | 3.0 | | Selling, marketing and administrative expenses | 16,923 | 16,416 | 3.1 | | Research and development expense | 10,413 | 11,934 | (12.7) | | In-process research and development impairments | — | 194 | N/A | | Interest (income) expense, net | (62) | (433) | N/A | | Other (income) expense, net | (7,692) | 4,855 | N/A | | Restructuring | 144 | 192 | (25.0) | | Earnings before provision for taxes on income | 27,615 | 12,800 | 115.7 | | Provision for taxes on income | 5,927 | 2,165 | 173.8 | | Net earnings | 21,688 | 10,635 | 103.9 | | Net earnings per share (Diluted) | 8.94 | 4.38 | 104.1 | | Effective tax rate | 21.5% | 16.9% | N/A | | Adjusted net earnings | 20,206 | 19,296 | 4.7 | | Adjusted net earnings per share (Diluted) | 8.33 | 7.94 | 4.9 | | Adjusted effective tax rate | 18.0% | 18.1% | N/A | Reconciliation of Non-GAAP Financial Measures This section reconciles non-GAAP financial measures, including adjusted net earnings and adjusted operational sales growth, to their most directly comparable GAAP measures Adjusted Net Earnings The company provides adjusted net earnings to offer a clearer view of operational performance by excluding special items such as litigation, intangible asset amortization, and restructuring costs. These adjustments significantly impact reported GAAP earnings Third Quarter Reconciliation of Adjusted Net Earnings - Third Quarter | Adjustment Category | 2025 ($M) | 2024 ($M) | | :---------------------------------- | :-------- | :-------- | | Net Earnings, after tax - as reported | 5,152 | 2,694 | | Pre-tax Adjustments: | | | | Litigation related | 15 | 2,388 | | Intangible Asset Amortization expense | 1,048 | 1,171 | | COVID-19 Vaccine related costs | — | 4 | | Restructuring related | 168 | 47 | | Medical Device Regulation | — | 38 | | Acquisition, integration and divestiture related | 97 | 328 | | (Gains)/losses on securities | (387) | (37) | | Other | 2 | — | | Tax Adjustments: | | | | Tax impact on special item adjustments | (168) | (762) | | Tax legislation and other tax related | 874 | 5 | | Adjusted Net Earnings, after tax | 6,801 | 5,876 | | Adjusted net earnings per share (Diluted) | 2.80 | 2.42 | - In fiscal 2025, the company initiated a restructuring program for its Surgery franchise within the MedTech segment, incurring $128 million in Q3 2025, primarily for asset impairments and market/product exits [10] - Restructuring expenses in the Orthopaedics franchise were $40 million in Q3 2025 and $28 million in Q3 2024, related to market and product exits [11] Nine Months Reconciliation of Adjusted Net Earnings - Nine Months | Adjustment Category | 2025 ($M) | 2024 ($M) | | :---------------------------------- | :-------- | :-------- | | Net Earnings, after tax - as reported | 21,688 | 10,635 | | Pre-tax Adjustments: | | | | Litigation related | (6,894) | 5,466 | | Intangible Asset Amortization expense | 3,435 | 3,355 | | COVID-19 Vaccine related costs | — | 77 | | Restructuring related | 302 | 207 | | Medical Device Regulation | — | 157 | | Acquisition, integration and divestiture related | 475 | 928 | | (Gains)/losses on securities | (327) | 374 | | IPR&D impairments | — | 194 | | Other | 29 | — | | Tax Adjustments: | | | | Tax impact on special item adjustments | 826 | (2,055) | | Tax legislation and other tax related | 672 | (42) | | Adjusted Net Earnings, after tax | 20,206 | 19,296 | | Adjusted net earnings per share (Diluted) | 8.33 | 7.94 | - In fiscal 2023, the company completed a prioritization of its R&D investment within the Innovative Medicine segment, leading to the exit of certain programs, primarily in infectious diseases and vaccines [13] - A restructuring program for the MedTech Surgery franchise was initiated in fiscal 2025, with $157 million in YTD costs primarily for asset impairments and market/product exits [14] Adjusted Operational Sales Growth Adjusted operational sales growth, which excludes the impact of acquisitions, divestitures, and currency fluctuations, provides a clearer picture of the underlying business performance. Both Innovative Medicine and MedTech segments showed positive adjusted operational growth Third Quarter Adjusted Operational Sales Growth - Third Quarter | Segment | WW As Reported (%) | WW Currency (%) | WW Operational (%) | Caplyta Impact (%) | All Other A&D Impact (%) | WW Adjusted Operational Ex A&D (%) | | :-------------------- | :----------------- | :-------------- | :----------------- | :----------------- | :----------------------- | :--------------------------------- | | Innovative Medicine | 6.8 | 1.5 | 5.3 | (1.6) | 0.0 | 3.7 | | MedTech | 6.8 | 1.2 | 5.6 | — | 0.1 | 5.7 | | Total | 6.8 | 1.4 | 5.4 | (1.1) | 0.1 | 4.4 | Nine Months Adjusted Operational Sales Growth - Nine Months | Segment | WW As Reported (%) | WW Currency (%) | WW Operational (%) | Shockwave Impact (%) | Caplyta Impact (%) | All Other A&D Impact (%) | WW Adjusted Operational Ex A&D (%) | | :-------------------- | :----------------- | :-------------- | :----------------- | :------------------- | :----------------- | :----------------------- | :--------------------------------- | | Innovative Medicine | 4.7 | 0.2 | 4.5 | — | (1.1) | 0.0 | 3.4 | | MedTech | 5.6 | 0.3 | 5.3 | (1.9) | — | 0.3 | 3.7 | | Total | 5.0 | 0.3 | 4.7 | (0.6) | (0.7) | 0.1 | 3.5 | Detailed Segment Sales This section provides a detailed breakdown of sales performance for the Innovative Medicine and MedTech segments, including key product categories and their respective growth rates Innovative Medicine Segment Sales The Innovative Medicine segment experienced overall growth, primarily driven by strong performance in Oncology and Neuroscience, while Immunology faced challenges due to declining sales of key products like STELARA Third Quarter Innovative Medicine Segment Sales - Third Quarter Summary | Segment | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | Total Innovative Medicine WW | 15,563 | 14,580 | 6.8 | 5.3 | | Oncology WW | 6,529 | 5,380 | 21.3 | 19.2 | | Immunology WW | 4,168 | 4,621 | (9.8) | (10.6) | | Neuroscience WW | 2,024 | 1,755 | 15.3 | 14.6 | | Pulmonary Hypertension WW | 1,115 | 1,102 | 1.1 | 0.4 | | Infectious Diseases WW | 829 | 836 | (0.9) | (4.3) | | Cardiovascular / Metabolism / Other WW | 899 | 884 | 1.7 | 1.2 | Oncology Oncology Product Sales - Third Quarter | Product | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | CARVYKTI | 524 | 286 | 83.5 | 81.4 | | DARZALEX | 3,672 | 3,016 | 21.7 | 19.9 | | ERLEADA | 936 | 790 | 18.4 | 15.3 | | IMBRUVICA | 695 | 753 | (7.8) | (10.6) | | RYBREVANT / LAZCLUZE | 198 | 89 | N/A | N/A | | TALVEY | 122 | 75 | 60.8 | 59.1 | | TECVAYLI | 177 | 135 | 31.3 | 29.9 | | ZYTIGA / abiraterone acetate | 113 | 150 | (25.1) | (26.8) | Immunology Immunology Product Sales - Third Quarter | Product | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | REMICADE | 476 | 419 | 13.6 | 13.3 | | SIMPONI / SIMPONI ARIA | 687 | 516 | 32.9 | 31.5 | | STELARA | 1,570 | 2,676 | (41.3) | (42.0) | | TREMFYA | 1,424 | 1,007 | 41.3 | 40.1 | Neuroscience Neuroscience Product Sales - Third Quarter | Product | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | CAPLYTA | 240 | — | N/A | N/A | | CONCERTA / methylphenidate | 140 | 142 | (1.4) | (1.8) | | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | 929 | 1,049 | (11.3) | (11.9) | | SPRAVATO | 459 | 284 | 61.5 | 60.8 | Pulmonary Hypertension Pulmonary Hypertension Product Sales - Third Quarter | Product | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | OPSUMIT / OPSYNVI | 578 | 583 | (0.8) | (1.7) | | UPTRAVI | 484 | 458 | 5.6 | 5.0 | Infectious Diseases Infectious Diseases Product Sales - Third Quarter | Product | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | EDURANT / rilpivirine | 385 | 330 | 16.4 | 9.5 | | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | 397 | 449 | (11.6) | (12.6) | Cardiovascular / Metabolism / Other Cardiovascular / Metabolism / Other Product Sales - Third Quarter | Product | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | XARELTO | 635 | 592 | 7.4 | 7.4 | Nine Months Innovative Medicine Segment Sales - Nine Months Summary | Segment | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | Total Innovative Medicine WW | 44,638 | 42,632 | 4.7 | 4.5 | | Oncology WW | 18,519 | 15,284 | 21.2 | 20.6 | | Immunology WW | 11,868 | 13,590 | (12.7) | (12.6) | | Neuroscience WW | 5,722 | 5,340 | 7.2 | 7.2 | | Pulmonary Hypertension WW | 3,253 | 3,190 | 2.0 | 1.8 | | Infectious Diseases WW | 2,434 | 2,622 | (7.2) | (8.3) | | Cardiovascular / Metabolism / Other WW | 2,842 | 2,605 | 9.1 | 9.2 | Oncology Oncology Product Sales - Nine Months | Product | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | CARVYKTI | 1,332 | 629 | N/A | N/A | | DARZALEX | 10,448 | 8,586 | 21.7 | 21.3 | | ERLEADA | 2,615 | 2,215 | 18.0 | 17.0 | | IMBRUVICA | 2,139 | 2,307 | (7.3) | (7.9) | | RYBREVANT / LAZCLUZE | 518 | 205 | N/A | N/A | | TALVEY | 314 | 202 | 55.3 | 54.9 | | TECVAYLI | 494 | 403 | 22.6 | 22.5 | | ZYTIGA / abiraterone acetate | 383 | 496 | (22.8) | (23.4) | Immunology Immunology Product Sales - Nine Months | Product | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | REMICADE | 1,398 | 1,246 | 12.2 | 12.7 | | SIMPONI / SIMPONI ARIA | 2,036 | 1,607 | 26.7 | 27.2 | | STELARA | 4,848 | 8,012 | (39.5) | (39.5) | | TREMFYA | 3,566 | 2,721 | 31.0 | 30.8 | Neuroscience Neuroscience Product Sales - Nine Months | Product | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | CAPLYTA | 451 | — | N/A | N/A | | CONCERTA / methylphenidate | 452 | 482 | (6.3) | (5.5) | | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | 2,824 | 3,159 | (10.6) | (10.5) | | SPRAVATO | 1,193 | 780 | 53.0 | 52.9 | Pulmonary Hypertension Pulmonary Hypertension Product Sales - Nine Months | Product | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | OPSUMIT / OPSYNVI | 1,682 | 1,655 | 1.7 | 1.4 | | UPTRAVI | 1,411 | 1,352 | 4.3 | 4.2 | Infectious Diseases Infectious Diseases Product Sales - Nine Months | Product | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | EDURANT / rilpivirine | 1,103 | 950 | 16.1 | 13.0 | | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | 1,196 | 1,305 | (8.3) | (8.4) | Cardiovascular / Metabolism / Other Cardiovascular / Metabolism / Other Product Sales - Nine Months | Product | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | XARELTO | 1,946 | 1,697 | 14.7 | 14.7 | MedTech Segment Sales The MedTech segment demonstrated consistent growth across most franchises, with Cardiovascular and Vision being strong performers. Orthopaedics experienced more modest growth or slight declines in certain areas Third Quarter MedTech Segment Sales - Third Quarter Summary | Segment | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | Total MedTech WW | 8,430 | 7,891 | 6.8 | 5.6 | | Cardiovascular WW | 2,213 | 1,966 | 12.6 | 11.6 | | Orthopaedics WW | 2,274 | 2,191 | 3.8 | 2.4 | | Surgery WW | 2,542 | 2,434 | 4.4 | 3.3 | | Vision WW | 1,400 | 1,300 | 7.7 | 6.1 | Cardiovascular Cardiovascular Product Sales - Third Quarter | Product | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | ELECTROPHYSIOLOGY | 1,418 | 1,279 | 10.8 | 9.7 | | ABIOMED | 423 | 362 | 16.8 | 15.6 | | SHOCKWAVE | 278 | 229 | 21.2 | 20.9 | Orthopaedics Orthopaedics Product Sales - Third Quarter | Product | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | HIPS | 405 | 381 | 6.4 | 5.1 | | KNEES | 377 | 352 | 7.0 | 5.6 | | TRAUMA | 793 | 761 | 4.2 | 2.9 | | SPINE, SPORTS & OTHER | 698 | 696 | 0.3 | (1.3) | Surgery Surgery Product Sales - Third Quarter | Product | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | ADVANCED | 1,165 | 1,109 | 5.0 | 3.8 | | GENERAL | 1,378 | 1,325 | 3.9 | 2.9 | Vision Vision Product Sales - Third Quarter | Product | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | CONTACT LENSES / OTHER | 1,018 | 968 | 5.2 | 3.5 | | SURGICAL | 383 | 333 | 14.9 | 13.8 | Nine Months MedTech Segment Sales - Nine Months Summary | Segment | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | Total MedTech WW | 24,991 | 23,669 | 5.6 | 5.3 | | Cardiovascular WW | 6,629 | 5,645 | 17.4 | 17.1 | | Orthopaedics WW | 6,820 | 6,843 | (0.3) | (0.8) | | Surgery WW | 7,493 | 7,338 | 2.1 | 2.1 | | Vision WW | 4,048 | 3,843 | 5.3 | 4.8 | Cardiovascular Cardiovascular Product Sales - Nine Months | Product | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | ELECTROPHYSIOLOGY | 4,209 | 3,946 | 6.7 | 6.4 | | ABIOMED | 1,291 | 1,112 | 16.1 | 15.5 | | SHOCKWAVE | 828 | 306 | N/A | N/A | Orthopaedics Orthopaedics Product Sales - Nine Months | Product | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | HIPS | 1,235 | 1,220 | 1.3 | 0.9 | | KNEES | 1,155 | 1,147 | 0.7 | 0.3 | | TRAUMA | 2,333 | 2,285 | 2.1 | 1.6 | | SPINE, SPORTS & OTHER | 2,096 | 2,191 | (4.3) | (5.0) | Surgery Surgery Product Sales - Nine Months | Product | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | ADVANCED | 3,402 | 3,337 | 1.9 | 1.8 | | GENERAL | 4,092 | 4,001 | 2.3 | 2.3 | Vision Vision Product Sales - Nine Months | Product | 2025 WW Sales ($M) | 2024 WW Sales ($M) | Reported % Change | Operational % Change | | :-------------------- | :----------------- | :----------------- | :---------------- | :------------------- | | CONTACT LENSES / OTHER | 2,902 | 2,796 | 3.8 | 3.1 | | SURGICAL | 1,147 | 1,048 | 9.4 | 9.6 |